SRR1797288
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.460
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.390
- MYC_TARGETS_V1+0.380
- MTORC1_SIGNALING+0.320
- MITOTIC_SPINDLE+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.280
- ANDROGEN_RESPONSE+0.230
- OXIDATIVE_PHOSPHORYLATION+0.230
- PI3K_AKT_MTOR_SIGNALING+0.210
Top 10 suppressed
- MYOGENESIS-0.320
- IL6_JAK_STAT3_SIGNALING-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- ALLOGRAFT_REJECTION-0.260
- INFLAMMATORY_RESPONSE-0.260
- KRAS_SIGNALING_UP-0.260
- ESTROGEN_RESPONSE_EARLY-0.250
- KRAS_SIGNALING_DN-0.250
- ESTROGEN_RESPONSE_LATE-0.240
- HEDGEHOG_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.899 |
| 2 | SRR1797299 | — | cohortSC | 0.898 |
| 3 | BS_G23JJAZY | Supratentorial Ependymoma | — | 0.892 |
| 4 | BS_7G42J2SK | EPN | Supratentorial EPN | 0.890 |
| 5 | TCGA-A2-A25E-01A-11R-A169-07 | — | B | 0.887 |
| 6 | BS_052PZFMK | high-grade glioma | — | 0.880 |
| 7 | R125 | — | — | 0.878 |
| 8 | BS_7G42J2SK | Supratentorial Ependymoma | — | 0.877 |
| 9 | TCGA-A2-A0YG-01A-21R-A109-07 | — | C | 0.877 |
| 10 | SRR13311183 | — | — | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |